Top-Rated StocksTop-RatedNASDAQ:TRVI Trevi Therapeutics (TRVI) Stock Price, News & Analysis $7.49 +0.16 (+2.18%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$7.48 -0.02 (-0.20%) As of 08/4/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Trevi Therapeutics Stock (NASDAQ:TRVI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Trevi Therapeutics alerts:Sign Up Key Stats Today's Range$7.20▼$7.5250-Day Range$5.47▼$7.8952-Week Range$2.36▼$8.11Volume1.10 million shsAverage Volume1.85 million shsMarket Capitalization$878.50 millionP/E RatioN/ADividend YieldN/APrice Target$20.88Consensus RatingBuy Company Overview Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Read More Trevi Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreTRVI MarketRank™: Trevi Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 390th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.7 / 5Analyst RatingBuy Consensus RatingTrevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.30, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTrevi Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Trevi Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevi Therapeutics is -16.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevi Therapeutics is -16.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevi Therapeutics has a P/B Ratio of 5.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Trevi Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.48% of the outstanding shares of Trevi Therapeutics have been sold short.Short Interest Ratio / Days to CoverTrevi Therapeutics has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Trevi Therapeutics has recently increased by 6,352.66%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTrevi Therapeutics does not currently pay a dividend.Dividend GrowthTrevi Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.48% of the outstanding shares of Trevi Therapeutics have been sold short.Short Interest Ratio / Days to CoverTrevi Therapeutics has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Trevi Therapeutics has recently increased by 6,352.66%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.46 News SentimentTrevi Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Trevi Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for TRVI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows14 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 180% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders18.30% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Trevi Therapeutics' insider trading history. Receive TRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRVI Stock News HeadlinesShort Interest in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Rises By 6,352.7%August 3 at 3:53 AM | americanbankingnews.comTrevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025July 31, 2025 | prnewswire.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative... | InvestorPlace (Ad)Trevi Therapeutics to Participate in Upcoming August ConferencesJuly 29, 2025 | prnewswire.comCantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight RecommendationJuly 2, 2025 | msn.comTRVI Trevi Therapeutics, Inc. - Seeking AlphaJuly 1, 2025 | seekingalpha.comTrevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and MetabolismJuly 1, 2025 | prnewswire.comTRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the FirmJune 26, 2025 | globenewswire.comSee More Headlines TRVI Stock Analysis - Frequently Asked Questions How have TRVI shares performed this year? Trevi Therapeutics' stock was trading at $4.12 at the start of the year. Since then, TRVI stock has increased by 81.8% and is now trading at $7.49. How were Trevi Therapeutics' earnings last quarter? Trevi Therapeutics, Inc. (NASDAQ:TRVI) posted its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.04. Read the conference call transcript. When did Trevi Therapeutics IPO? Trevi Therapeutics (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager. Who are Trevi Therapeutics' major shareholders? Top institutional shareholders of Trevi Therapeutics include Y Intercept Hong Kong Ltd (0.07%), Vontobel Holding Ltd. (0.02%), Diversified Trust Co (0.02%) and Kingswood Wealth Advisors LLC (0.01%). Insiders that own company stock include David P Meeker, Thomas Sciascia, Jennifer L Good, Farrell Simon and Lisa Delfini. View institutional ownership trends. How do I buy shares of Trevi Therapeutics? Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Trevi Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC). Company Calendar Last Earnings5/06/2025Today8/04/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRVI CIK1563880 Webwww.trevitherapeutics.com Phone(203) 304-2499FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Trevi Therapeutics$20.88 High Price Target$29.00 Low Price Target$7.00 Potential Upside/Downside+178.7%Consensus RatingBuy Rating Score (0-4)3.30 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$47.91 million Net MarginsN/A Pretax MarginN/A Return on Equity-58.41% Return on Assets-52.52% Debt Debt-to-Equity RatioN/A Current Ratio15.38 Quick Ratio15.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book5.76Miscellaneous Outstanding Shares117,290,000Free Float95,828,000Market Cap$878.50 million OptionableOptionable Beta0.58 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:TRVI) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.